Kimberly Spoerri’s practice focuses on public and private mergers and acquisitions, private equity investments, and corporate governance matters.

Kim joined the firm in 2008 and became partner in 2017.

Notable Experience

  • GiVi Holding (the Versace Family holding company of Gianni Versace S.p.A.) and Donatella Versace in connection with the announced sale of Versace to Michael Kors Holdings Ltd. for $2.13 billion.

  • Takeda Pharmaceutical Company in its $5.2 billion acquisition of ARIAD Pharmaceuticals.

  • Merck & Co. in its joint venture with Sanofi Pasteur for the exploitation of hexavalent vaccine Vaxelis.

  • Google in a variety of transactions, including its acquisitions of Orbitera, Waze and Motorola Mobility.

  • Alimentation Couche-Tard in its acquisition of Holiday Stationstores.

  • Warburg Pincus in its acquisition of Electronic Funds Source and the subsequent sale of EFS to WEX Inc.

  • Allergan in its announced $160 billion merger with Pfizer.

  • Honeywell in connection with various proposed spin-off transactions.

  • Goldman Sachs, as financial advisor, in various transactions.

  • The Raine Group and Temasek in an investment in SoundCloud.

  • American Tower in its $5 billion acquisition of over 11,000 wireless communications towers from Verizon.

  • Genting Hong Kong as a shareholder of Norwegian Cruise Line in NCL’s $3 billion acquisition of Prestige Cruises International.

  • OneWest Bank in its $3.4 billion sale to CIT Group.

  • Lenovo in its $2.3 billion acquisition of IBM’s x86 server business.

  • Pluspetrol Resources Corporation N.V. in its acquisition of Apco Oil and Gas International, Inc., and in its acquisition of substantially all of the assets of Harvest Natural Resources, Inc.

  • BHP Copper Inc., a subsidiary of BHP Billiton in the sale of its Pinto Valley copper mining operations and the San Manuel Arizona Railroad Company to Capstone Mining.

  • The Home Depot in its acquisition of BlackLocus and Redbeacon.

  • Conversus Capital in the $1.4 billion sale of its portfolio of third-party private equity fund interests to HarbourVest Partners.

  • GlaxoSmithKline in its unsolicited tender offer to acquire Human Genome Sciences and the resulting negotiated acquisition for $3.6 billion and its $2.9 billion acquisition of Steifel Laboratories.

See More

Selected Activities

Senior Executive Editor, Law Review, New York University School of Law